Qiagen NV (QGEN)
NYSE:QGEN
Top Page
Qiagen
(NYSE:QGEN)
Select Model
Select Model
Rating:72Outperform
Price Target:
$44.00
▲(8.29% Upside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by improved 2025 financial performance and a supportive outlook for continued profitable growth in 2026, tempered by historical earnings/cash-flow variability and near-term operational headwinds. Technicals are constructive but not strongly bullish, while valuation is helped by the high dividend yield despite a mid-range P/E.
Positive Factors
Recurring consumables revenue & installed base
A large installed base and high-growth consumables (e.g., liquid-biopsy prep) underpin predictable, repeat revenue and durable pull-through. That business model supports steady revenue and margin resilience versus one-off instrument sales, helping multi-quarter visibility and cash flow stability.
Negative Factors
Historical earnings and cash‑flow volatility
Past swings in revenue, margins and cash conversion indicate earnings sensitivity to product cycles, OEM contributions and working capital. That variability raises execution risk: weaker demand or mis-timed investments could quickly reverse margin gains and constrain capital deployment or credit flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue & installed base
A large installed base and high-growth consumables (e.g., liquid-biopsy prep) underpin predictable, repeat revenue and durable pull-through. That business model supports steady revenue and margin resilience versus one-off instrument sales, helping multi-quarter visibility and cash flow stability.
Read all positive factors
Qiagen (QGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.40B
Dividend Yield3.31%
Average Volume (3M)2.00M
Price to Earnings (P/E)23.2
Beta (1Y)0.67
Revenue Growth5.32%
EPS Growth336.29%
CountryUS
Employees5,700
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.62
Shares Outstanding206,800,000
10 Day Avg. Volume2,220,041
30 Day Avg. Volume1,996,425
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue4.31
Enterprise Value/Gross Profit6.97
Enterprise Value/Ebitda12.55
Forecast
1Y Price Target
$55.14Price Target Upside35.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)2.52
Revenue Forecast (FY)$2.22B
Qiagen Business Overview & Revenue Model
Company Description
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sampl...
How the Company Makes Money
QIAGEN primarily makes money by selling (1) consumables and kits and (2) instruments and related services/software to laboratories and clinical customers. A large portion of revenue is recurring because many of its products are single-use or repea...
Qiagen Key Performance Indicators (KPIs)
Qiagen Earnings Call Summary
Earnings Call Date:Feb 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 04, 2026
Earnings Call Sentiment Positive
The call presents a broadly positive operational and financial picture: QIAGEN beat Q4 and full-year outlooks, delivered margin expansion and strong free cash flow, progressed multiple growth pillars (Sample Technologies, QuantiFERON, QIAstat, QIAcuity, QDI), completed strategic acquisitions (Parse, Genoox) and set 2026 guidance for continued profitable growth. Notable near-term challenges include declines in PCR/NGS consumables, regional softness (U.S. and China), tariff and FX headwinds, and short-term dilution from Parse and discontinued product lines that weigh on Q1/first-half 2026. Management expects improvement and acceleration into H2 2026 driven by new product launches and strengthened growth pillars.Positive Updates
Q4 Results Above Outlook
Net sales of $540M in Q4 2025, up 1% at constant exchange rates (CER) and ahead of outlook (which assumed flat sales). Adjusted diluted EPS was $0.62 at CER vs. outlook of about $0.60.
Negative Updates
PCR Product Group Decline
PCR product group sales declined 9% CER in Q4 2025; while QIAcuity consumables grew, sales of other PCR consumables fell due to a cautious funding environment and lower OEM contributions versus 2024.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Results Above Outlook
Net sales of $540M in Q4 2025, up 1% at constant exchange rates (CER) and ahead of outlook (which assumed flat sales). Adjusted diluted EPS was $0.62 at CER vs. outlook of about $0.60.
Read all positive updates
Company Guidance
QIAGEN guided 2026 to at least 5% sales growth at constant exchange rates (CER) and adjusted diluted EPS of at least $2.50 at CER, while expecting the adjusted operating income margin to remain about 29.5% (despite ~160 basis points of headwinds from the Parse acquisition, tariffs and FX); currency is expected to be a ~1‑point tailwind to full‑year sales (neutral to EPS) and ~2–3 points tailwind to Q1 sales. For Q1 the company expects net sales growth of at least 1% CER versus Q1‑25 ($483 million) and adjusted EPS of at least $0.54 at CER (vs $0.55 a year ago), noting Q1 headwinds of roughly $10M from the discontinuation of NeuMoDx/Dialunox (~2 percentage points), ~$10M from cautious life‑science spending (~2 points), and a low‑single‑digit QuantiFERON comparison (≈$6–7M, ~1 point); Parse will dilute Q1 EPS by ~$0.02 and U.S. tariffs by ~ $0.02. Management expects H1 growth of roughly 2–3% CER with an H2 acceleration to reach the full‑year target, a normalized run rate near 6% CER after roll‑offs, a currency‑neutral EPS impact, and continued focus on growth pillars (targeting ~9% CER growth in 2026 with Sample Technologies ≈ $720M, QuantiFERON ≈ $535M, QIAstat ≈ $160M, QIAcuity ≈ $100M and QDI ≈ $125M); the company completed a $500M share repurchase in January and shows pro‑forma leverage of ~1.3x net debt/adjusted EBITDA.Qiagen Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.09B | 1.98B | 1.97B | 2.14B | 2.25B |
| Gross Profit | 1.29B | 967.35M | 1.23B | 1.38B | 1.45B |
| EBITDA | 717.27M | 368.26M | 688.55M | 779.36M | 895.24M |
| Net Income | 424.88M | 83.59M | 341.30M | 423.21M | 512.60M |
Balance Sheet | |||||
| Total Assets | 6.30B | 5.69B | 6.12B | 6.29B | 6.15B |
| Cash, Cash Equivalents and Short-Term Investments | 1.10B | 1.15B | 1.06B | 1.42B | 1.07B |
| Total Debt | 1.65B | 1.61B | 1.69B | 2.03B | 2.12B |
| Total Liabilities | 2.52B | 2.12B | 2.31B | 2.82B | 3.05B |
| Stockholders Equity | 3.78B | 3.57B | 3.81B | 3.47B | 3.10B |
Cash Flow | |||||
| Free Cash Flow | 453.28M | 506.38M | 296.65M | 565.93M | 432.47M |
| Operating Cash Flow | 654.33M | 673.55M | 459.45M | 715.26M | 639.00M |
| Investing Cash Flow | -305.28M | -249.23M | -87.66M | -726.76M | -202.43M |
| Financing Cash Flow | -178.98M | -422.90M | -433.83M | -125.80M | -150.37M |
Qiagen Technical Analysis
Negative
40.63
Price Trends
47.97
Negative
46.91
Negative
47.33
Negative
Market Momentum
-2.36
Positive
31.77
Neutral
22.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Negative. The current price of 40.63 is below the 20-day moving average (MA) of 43.29, below the 50-day MA of 47.97, and below the 200-day MA of 47.33, indicating a bearish trend. The MACD of -2.36 indicates Positive momentum. The RSI at 31.77 is Neutral, neither overbought nor oversold. The STOCH value of 22.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QGEN.
Qiagen Risk Analysis
Qiagen disclosed 38 risk factors in its most recent earnings report. Qiagen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Qiagen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $8.40B | 23.17 | 11.85% | 3.31% | 5.32% | 336.29% | |
67 Neutral | $45.84B | 51.15 | 69.78% | ― | 8.39% | 21.44% | |
64 Neutral | $9.82B | 27.94 | 3.24% | 0.29% | 3.37% | -18.80% | |
63 Neutral | $182.31B | 32.34 | 13.15% | 0.30% | 3.91% | 7.09% | |
59 Neutral | $19.30B | 24.21 | 34.94% | ― | -2.39% | ― | |
59 Neutral | $28.11B | 28.49 | 22.28% | ― | 3.85% | -4.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
QGEN
Qiagen
40.63
1.12
2.83%
IDXX
Idexx Laboratories
575.72
153.18
36.25%
ILMN
Illumina
126.20
43.92
53.38%
RVTY
Revvity
87.84
-19.20
-17.93%
TMO
Thermo Fisher
490.77
-19.03
-3.73%
IQV
IQVIA Holdings
165.64
-13.72
-7.65%
Qiagen Corporate Events
Qiagen Tops 2025 Guidance and Sets Ambitious 2026 Growth Targets
Feb 6, 2026
On February 4, 2026, Qiagen reported unaudited results for the fourth quarter and full year ended December 31, 2025, posting Q4 net sales of $540 million, up 4% year on year (1% at constant exchange rates), and diluted EPS of $0.49, with adjusted ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.